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Treatment evaluation of patients with glioblastomas is important to aid in clinical decisions. Conventional MRI with con-
trast is currently the standard method, but unable to differentiate tumor progression from treatment-related effects. Pseu-
doprogression appears as new enhancement, and thus mimics tumor progression on conventional MRI. Contrarily, a
decrease in enhancement or edema on conventional MRI during antiangiogenic treatment can be due to pseudoresponse
and is not necessarily reﬂective of a favorable outcome. Neovascularization is a hallmark of tumor progression but not for
posttherapeutic effects. Perfusion-weighted MRI provides a plethora of additional parameters that can help to identify this
neovascularization. This review shows that perfusion MRI aids to identify tumor progression, pseudoprogression, and pseu-
doresponse. The review provides an overview of the most applicable perfusion MRI methods and their limitations. Finally,
future developments and remaining challenges of perfusion MRI in treatment evaluation in neuro-oncology are discussed.
Level of Evidence: 3
Technical Efﬁcacy: Stage 4
J. MAGN. RESON. IMAGING 2019;49:11–22.
GLIOBLASTOMAS (GBMs) are highly malignant braintumors with a poor prognosis.1 It is important to distin-
guish patients with a GBM who respond to treatment from
patients who do not respond to treatment. Patients who do
not respond to treatment can undergo an expensive and
potentially harmful treatment, which should thus be discon-
tinued. Moreover, clinical trials investigating new therapeutic
agents should rely on adequate evaluation of treatment
response. It is currently not possible to reliably differentiate
tumor progression from treatment-related changes with con-
ventional imaging techniques. Improvement of treatment
evaluation in neuro-oncology is therefore necessary.
Treatment response evaluation in neuro-oncology is
highly dependent on imaging. Magnetic resonance imaging
(MRI) with its excellent soft-tissue contrast, high spatial reso-
lution, and widespread availability has become the standard
method. However, conventional MRI has one important lim-
itation: the inability to differentiate tumor from treatment-
related changes.2 Tumor progression will most often result in
increased enhancement on postcontrast MRI. However,
enhancement can also be due to a treatment-related blood–
brain barrier disruption without underlying tumor progres-
sion. This is called pseudoprogression.3,4 Furthermore, anti-
angiogenic treatment can result in a decrease of enhancement
on postcontrast MRI while the tumor remains stable or even
increases. This is called pseudoresponse. Thus, posttherapeu-
tic effects such as pseudoprogression and pseudoresponse hin-
der a reliable treatment evaluation.
Perfusion-weighted MRI provides a plethora of addi-
tional parameters to overcome the shortcomings of conven-
tional MRI. Perfusion MRI can be used to image
neovascularization, a hallmark of tumor progression. The net
result of neovascularization is an extensive network of poorly
organized tumor vessels. Tumor vessels are tortuous, often
large and uneven in diameter, slow ﬂowing, and leaky.5–7
Leakage of contrast from tumor vessels is visible as enhance-
ment on conventional postcontrast T1-weighted MRI. How-
ever, with perfusion MRI it is possible to determine the
blood volume and ﬂow as well as the leakage component,
thereby extending information about the tumor vasculature.
This review will show the potential value of perfusion MRI
during treatment evaluation of GBMs. The different perfu-
sion techniques with their advantages and disadvantages are
discussed. Finally, novel perfusion techniques and future chal-
lenges are addressed.
PERFUSION TECHNIQUES
The most frequently used perfusion MRI techniques include
dynamic susceptibility contrast (DSC) imaging (Figs. 1–2),
FIGURE 1: Dynamic susceptibility contrast (DSC) case of tumor progression. A case of tumor progression in a 68-year-old male after
3 months postchemoradiotherapy. Anatomical MRI pre- (a) and postcontrast (b) T1-weighted imaging demonstrated new
enhancement and increased FLAIR signal (c) Dynamic susceptibility contrast (DSC) perfusion imaging (d) conﬁrmed tumor
progression with elevated rCBV values located at the place of contrast enhancement as indicated by the white circles.
DSC = dynamic susceptibility contrast, rCBV = relative cerebral blood volume.
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dynamic contrast-enhanced (DCE) imaging, and arterial spin
labeling (ASL) (Fig. 3). An overview of the different perfusion
techniques and their advantages and limitations is shown in
Table 1.
Dynamic Susceptibility Contrast
DSC is the most widely applied perfusion method.8,9 DSC is
acquired with rapid echo planar imaging (EPI) and relies on a
drop in T*2 signal after passage of a gadolinium-based contrast
bolus.10 The loss in the signal intensity–time curve due to
susceptibility effects of the contrast agent corresponds to the
concentration of the contrast agent. DSC can be performed
on both 1.5T and 3T systems. A bolus of contrast agent
(0.1 mmol/kg) should be administered 20 seconds (5–30)
after the start of acquisition at a minimal injection rate of
3 mL/s.11,12 The use of a preload bolus is also recommended
to limit leakage effects in DSC, with a ¼ dosage given as
preload at the same injection rate 5–10 minutes prior to
the 3/4 remaining bolus.12 Various hemodynamic parameters
can be calculated from the concentration–time curves.11
The relative cerebral blood volume in a given amount of tis-
sue (rCBV) is the most studied parameter.13 The ratio of
rCBV compared with contralateral normal-appearing white
matter is often calculated for quantiﬁcation. Other parame-
ters are relative cerebral blood ﬂow (rCBF), the volume of
blood in a given amount of tissue per unit of time, and
mean transit time (MTT), the average time red blood cells
spend within a determinate volume of capillaries, which can
be calculated by dividing the rCBV by the rCBF. Less fre-
quently studied DSC-derived parameters include relative
peak height, the difference in baseline signal intensity and
minimum signal intensity in the perfusion curve, and per-
centage of signal recovery, which corresponds to the degree
of residual T*2 signal loss.
DSC acquisition can be achieved relatively fast and is
widely available compared with other perfusion techniques.8
Absolute quantiﬁcation, however, can be troublesome and
manual region selection is necessary, making the technique
user-dependent. DSC relies on the assumption that the con-
trast agent remains intravascular. Extravasation of the contrast
agent due to the disrupted blood–brain barrier in GBM lead-
ing to T1- and T
*
2-relaxation effects can cause an underesti-
mation or overestimation of rCBV, respectively.14 The use of
a preload contrast bolus and leakage correction algorithms
FIGURE 2: Dynamic susceptibility contrast (DSC) in a patient with pseudoprogression. Pseudoprogression in a 35-year-old male
6 months after completion of chemoradiotherapy. Pre- (a) and postcontrast T1-weighted imaging (b) and FLAIR (c) were both
suggestive of apparent progressive disease. However, DSC (d) correctly showed that these changes were due to
pseudoprogression, as rCBV values were not elevated at the location of the enhancing lesion (white circles). DSC = dynamic
susceptibility contrast, rCBV = relative cerebral blood volume.
FIGURE 3: Arterial spin labeling (ASL) in recurrent glioblastoma. Follow-up imaging of a 40-year-old female with a glioblastoma
3 months after partial resection and chemoradiotherapy. Pre- (a) and postcontrast T1-weighted (b) and FLAIR (c) images showed a
signiﬁcant increase of the lesion. ASL perfusion imaging (d) was in accordance with the anatomical images, demonstrating increased
CBF values (yellow) corresponding with tumor progression. ASL = arterial spin labeling, rCBF = cerebral blood ﬂow.
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partially balance these leakage effects.14,15 Other intravascular
contrast agents such as an ultrasmall superparamagnetic iron
oxide or an albumin-binding agent have also been studied to
tackle the issue of leakage effects.16,17 Ultrasmall superpara-
magnetic iron oxide particles are larger than gadolinium
compounds and hence remain intravascular, even when dis-
ruption of the blood–brain barrier is present. The downside
of these agents, however, is that they do not allow measures
of permeability and extracellular volume, and little experience
with these agents exist. Furthermore, susceptibility artifacts
TABLE 1. Overview of Perfusion MRI Methods in Treatment Evaluation of Glioblastoma
DSC DCE ASL
Sequence T2* EPI T1 spoiled-GRE T1 EPI, FSE
Slice thickness 3–5 mm 2–10 mm 5–10 mm
Temporal resolution 1–1.5 sec 4–6 sec 3–5 sec
Contrast injection rate 3–5 mL/s 2–4 mL/s No contrast
Acquisition time 2–3 min 3–7 min 4–10 min
Parameters rCBV
rCBF
MTT
PH
PSR
Ktrans
Ve
Vp
AUC
rCBF
ATT
Advantages short acquisition time
widely available
visually inspection
microvascular permeability
higher spatial resolution
no leakage correction needed
no contrast required
Disadvantages quantiﬁcation
user-dependent
susceptibility artifacts
postprocessing
complex pharmacokinetic modeling
low signal-to-noise ratio
risk of movement artifacts
ASL = arterial spin labeling, ATT = arterial transit time, AUC = area under the curve, DCE = dynamic contrast enhanced, DSC =
dynamic susceptibility contrast, EPI = echo planar imaging, FSE = fast spin echo, GRE = gradient echo, Ktrans = volume transfer coefﬁ-
cient, MMT = mean transfer time, PH = peak height, PSR = percentage of signal recovery, rCBF = cerebral blood ﬂow, rCBV = relative
cerebral blood volume, Ve = extravascular volume, Vp = plasma volume.
FIGURE 4: Susceptibility artifact on dynamic susceptibility contrast (DSC) perfusion MRI. Postoperative imaging after resection of a
glioblastoma in a 65-year-old female. The resection cavity contains a hemorrhage (circle) as demonstrated on precontrast T1-
weighted imaging (a). Unprocessed DSC imaging demonstrated a large susceptibility artifact in the area of the blood products and
surgical material after craniotomy (b). The calculated DSC-rCBV is therefore not assessable with artifactual low values (c). Note also a
susceptibility artifact frontally (asterisk) due to the skull base and frontal sinuses with bone-air interfaces (b). DSC = dynamic
susceptibility contrast, rCBV = relative cerebral blood volume.
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occur frequently with DSC. Based on the T*2 acquisition of
DSC, there is a signal loss due to blood products, calciﬁca-
tions, and aerated structures. As blood is often present within
the resection cavity postoperatively, this potentially hinders a
reliable interpretation (Fig. 4).
Dynamic Contrast-Enhanced
With DCE T1-weighted spoiled gradient-recalled echo, images
are acquired during the administration of a gadolinium-based
contrast agent with an injection rate of 2–4 mL/s.11,18 A
signal-intensity curve results from the acquisition and is reﬂec-
tive of perfusion, permeability, and extravascular volume mea-
sures. Due to the increased permeability of tumor vasculature,
intravascular ﬂuid will leak into the extravascular extracellular
space.18 The parameters that can be calculated from DCE
images are the volume transfer coefﬁcient from the blood
plasma to the extracellular space (Ktrans), the extracellular vol-
ume (Ve), plasma space volume (Vp), and area under the curve
(AUC).2,11 Basic features of the signal-intensity curve such as
AUC can be extracted easily without the need of a model.
However, calculation of most quantitative DCE parameters
requires pharmacokinetic modeling. It is possible to incorpo-
rate DCE imaging in a multisequence protocol along with
DSC. Performing DCE before DSC is recommended, as the
ﬁrst contrast injection then functions as a preload bolus and
simultaneously allows calculations of permeability.11
DCE is said to better and more completely demonstrate
angiogenesis processes, as it is capable of showing microvascu-
lar permeability. Furthermore, quantitative assessment of the
blood–brain barrier is possible with DCE. As DCE is acquired
with a T1-weighted sequence, it has a lower temporal resolu-
tion than DSC (Table 1). The lower temporal resolution of
DCE may not be optimal to adequately extract all parame-
ters.18 Other disadvantages of DCE include postprocessing
and quantiﬁcation of the images, as there is currently no con-
sensus for the optimal pharmacokinetic model.19 The Tofts-
Kermode model and Extended Tofts-Kermode model are the
best-established models, but many more are available.19,20 It is
known that different pharmacokinetic models lead to different
measures of Ktrans.18 Therefore, parameters acquired by differ-
ent models are not intercomparable. Moreover, pharmacoki-
netic models require an arterial input function. Determination
of the arterial input function is not straightforward and often
still relies on manual input.21 Differences of these variables
across institutions hinder reproducibility and generalizability.
Arterial Spin Labeling
Contrary to the aforementioned techniques, ASL is not
dependent on exogenous contrast agents, and thus is
completely noninvasive. In ASL, water molecules from arterial
blood are magnetically labeled and followed till they arrive in
the tissue of interest.22 The signal difference between the
labeled images and separately acquired control images can be
used to compute CBF values.23 Several methods of ASL
imaging currently exist but pseudocontinuous ASL is now
widely accepted as the method of choice.22,24 In pseudocon-
tinuous ASL a relatively long labeling time (2–4 sec) is used
consisting of a series of very short radiofrequency pulses, with
a spacing of 1 msec between pulses.24 After a postlabeling
delay of 1.5–2 seconds, allowing the labeled blood to arrive
in the brain tissue, the images are acquired.22,25 All arterial
blood has equal T1 decay, as it is continuously inverted as it
passes through the labeling plane, making pseudocontinuous
ASL superior to other ASL methods.23 The labeling plane
should be placed in a region with relatively straight feeding
arteries perpendicular to the labeling plane.22,24 Traditionally,
EPI was used to acquire ASL, but nowadays fast spin echo
and 3D gradient and spin echo can be applied with the
advantage of single-shot acquisition.22 Although ASL is also
possible on 1.5T MR systems, 3T scanners reach a higher sig-
nal to noise ratio (SNR) and are therefore preferred.
A major advantage of ASL compared with other perfu-
sion techniques is the avoidance of leakage effects. Leakage
correction, such as in DSC, is not needed in ASL, as the
tracer (water) is diffusible.11,23 Direct beneﬁcial effects of
contrast avoidance are limited as GBM patients receive con-
trast for anatomical MRI acquisition. Even though the SNR
is lower in pseudocontinuous ASL than pulsed ASL, SNR in
ASL is still lower compared with DSC and DCE. Therefore,
the scan time is prolonged in ASL with the consequential risk
of movement artifacts.11 Other frequently occurring artifacts
include susceptibility artifacts, blurring, and diminished back-
ground suppression.25 Furthermore, the number of parame-
ters that can be generated with ALS are limited, with CBF
being the most frequently generated parameter. However, it
has been shown that ASL-derived CBF values correlate well
with rCBV values acquired with DCS perfusion.22 Other
parameters such as arterial transit time26 are also producible
with ASL, but their clinical relevance remains to be further
explored.
PSEUDOPROGRESSION
Pseudoprogression is a transient treatment effect appearing as
new enhancement on conventional postcontrast MRI, thereby
mimicking tumor progression. Pseudoprogression is a fre-
quently encountered problem; a recent meta-analysis reported
the incidence of pseudoprogression during standard treat-
ment1 to be 36% (95% conﬁdence interval [CI] 33–40) in
GBM.27 Even higher rates of pseudoprogression were
reported in patients with methylated O6-methylguanine
methyltransferase (MGMT) status and wildtype isocitrate
dehydrogenase (IDH) gene status.3,28 Pseudoprogression typi-
cally occurs within 3 months after termination of treatment
and is usually transient. However, delayed effects up to years
after treatment can be seen. This radiation necrosis is often
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progressive and irreversible.3 Pseudoprogression is most likely
the result of vasodilatation, a disrupted blood–brain barrier,
and vasogenic edema due to radiation and chemotherapy
damage.3 In radiation necrosis, irreversible fybronoid necrosis,
ﬁbrosis, reactive gliosis, demyelination, and vascular hyaliniza-
tion are seen.29 Although radiotherapy planning has become
more and more precise in minimizing exposure of healthy
brain tissue, damage to noncancerous brain is inevitable due
to the inﬁltrative nature of GBMs. Clinically, pseudoprogres-
sion can be accompanied by a variety of clinical symptoms,
such as headache, nausea, emesis, and neurological deﬁcits.
This further complicates the distinction from tumor progres-
sion, as these symptoms can also accompany tumor progres-
sion. The distinction between pseudoprogression and early
tumor progression therefore remains a clinical challenge in
posttherapeutic neuro-oncology.
Perfusion MRI is more reliable than conventional MRI
in the differentiation between pseudoprogression and tumor
progression. A recent meta-analysis demonstrated a pooled
sensitivity and speciﬁcity of 87% (95% CI 82–91) and 86%
(77–91) for DSC and 92% (73–98) and 85% (76–92) for
DCE, respectively.30 The limited studies available for ASL to
differentiate tumor progression from pseudoprogression
showed a sensitivity ranging from 52–79% and a speciﬁcity
ranging from 64–82%.30 A table listing key information of
included clinical studies/surveys such as authors, study design
including MRI techniques and patient population, major
ﬁndings, and year of publication can be found in our recent
meta-analysis.30
The most validated DSC parameter is rCBV. Although
CBV can be visually inspected,31 it is usually quantiﬁed using
contralateral values to normalize values.10 Several studies have
shown that rCBV values are higher in tumor progression
(Fig. 1) than treatment effects (Fig. 2).30,32,33 rCBV is high in
tumor, as it is reﬂective of the tumor hyperperfusion volume.
However, the optimum rCBV threshold for differentiating
between tumor and treatment effects varies signiﬁcantly
between studies (range 0.71–3.7).30 rCBF can also be col-
lected with DSC imaging but is not often applied in neuro-
oncology treatment evaluation. Only one study reported the
use of DSC-derived rCBF for differentiating tumor recurrence
from stable disease with diagnostic accuracy comparable to
rCBV.34 Other DSC-derived parameters such as peak height
and percentage of signal recovery were signiﬁcantly higher in
tumor progression than pseudoprogression.35–37 However,
these parameters were all outperformed by rCBV.2,30
DCE demonstrates an even higher diagnostic accuracy
for differentiating pseudoprogression from tumor progres-
sion.30 This can in part be explained by the parameter Ktrans,
which is thought to reﬂect the increased capillary permeability
of leaky tumor vessels. Along with Ktrans, most experience is
gained with AUC for DCE. Bisdas et al prospectively com-
pared Ktrans and AUC in 18 treated high-grade glioma
patients and found higher sensitivity and speciﬁcity of Ktrans
(100% and 83%, respectively) than of AUC (75% and 67%,
respectively).38 Others recently conﬁrmed that there is a sig-
niﬁcant difference in Ktrans values between patients with
tumor progression and pseudoprogression, with higher values
for the latter.39 In addition, they were able to show a differ-
ence in mean Ve values, demonstrating a prognostic accuracy
of 88% when a cutoff value of 0.873 was used.39 However,
the deﬁciency of uniform thresholds due to a lack of unifor-
mity in data acquisition and pharmacokinetic models remains
troublesome.
FIGURE 5: Pseudoresponse identiﬁed by dynamic susceptibility contrast (DSC). Patient with a recurrent glioblastoma with new
contrast enhancement on T1-weighted MRI after completion of chemotherapy (a). The patient received second-line antiangiogenic
treatment with bevacizumab. After the ﬁrst course, follow-up MRI (b) showed a decrease in contrast-enhancing lesions (white circle),
suggestive of apparent response. However, DSC demonstrated persisting high perfusion values (arrows) conﬁrming the changes
were due to pseudoresponse (c). Subsequent follow-up scans demonstrated an increase in contrast enhancement and rCBV and the
patient deteriorated. DSC = dynamic susceptibility contrast, rCBV = relative cerebral blood volume.
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ASL studies for treatment evaluation in GBM are lim-
ited. The previously mentioned meta-analysis identiﬁed only
two ASL studies, reporting disappointing diagnostic accu-
racy.30,34,40 Moreover, these studies showed large differences
in sensitivity and speciﬁcity.30 ASL demonstrates tumor pro-
gression as high rCBF values (Fig. 3). A higher imaging qual-
ity has been reported in ASL in comparison to DSC for the
differentiation between tumor progression and pseudopro-
gression using rCBF values.41 Although ASL and DSC were
both capable of reliably differentiating between progression
and pseudoprogression, DSC reached a higher diagnostic
accuracy in this study.41 However, another study suggested
that ASL could outperform DSC when using a normalized
CBF cutoff ratio of 1.3.31
PSEUDORESPONSE
Due to unsatisfying survival rates, trials have investigated
novel treatment strategies, including antiangiogenic agents.
During antiangiogenic treatment a rapid decrease in contrast
enhancement and peritumoral edema is often seen on con-
ventional imaging.42 These radiological changes are reported
in 25–60% of the patients undergoing antiangiogenic treat-
ment.43 A ﬁrst decrease in contrast enhancement and edema
can be seen after several days. Mostly this radiological pattern
goes together with a temporary improvement of clinical
symptoms.44 However, the decrease in contrast enhancement
in pseudoresponse is not associated with a decrease in tumor
or survival improvement.44
Antiangiogenic treatment can potentially focus on
any of the proangiogenic factors involved in GBM neovas-
cularization. However, most current strategies are aimed at
vascular endothelial growth factor (VEGF) or its receptor.
Most studied agents are bevacizumab, a recombinant
monoclonal VEGF-A antibody, and cediranib, a pan-
VEGF receptor tyrosine kinase inhibitor. Antiangiogenic
treatment is thought to induce tumor hypoxia and tempo-
rarily normalize vascularization, thereby enhancing the
delivery of chemotherapy and radiotherapy. Initial trial
results were promising but included patients with pseudor-
esponse, hindering a reliable assessment of their value. Up
to now, most randomized controlled trials studying antian-
giogenic agents have failed to show a favorable effect on
survival of GBM patients after exclusion of patients with
pseudoresponse.45,46 However, active phase III trials are
still ongoing. Furthermore, pseudoresponse might also
occur during treatment with immunotherapeutic agents,
which are currently under investigation in many clinical
trials.47
Pseudoresponse typically involves a rapid decrease in
contrast enhancement on T1 and FLAIR signal after adminis-
tration of antiangiogenic agents. Perfusion MRI, however,
can demonstrate persistent increased perfusion values within
the apparently responsive lesion (Fig. 5). One study aimed to
distinguish true responders from nonresponders with DSC
after treatment with a non-VEGF protein kinase inhibitor
(enzastaurin) in addition to temozolomide.48 The authors
showed that responders demonstrated a decrease in DSC-
derived peak height and an increase in percentage of signal
recovery parameters.48 The increase in percentage of signal
recovery was suggestive of an improvement in vessel perme-
ability due to enzastaurin. Contrary to these ﬁndings, a DSC
study in 18 recurrent GBM patients did not ﬁnd signiﬁcant
differences in absolute CBV values between true treatment
responders and pseudoresponders.49
Rapid normalization of vessel permeability associated
with antiangiogenic treatment has been demonstrated by early
decreases in Ktrans using DCE perfusion.50,51 This decrease in
Ktrans was also associated with improvement of outcome in
one study.51 A phase II trial investigating the effect of adding
cediranib to standard treatment showed an early decrease in
Ktrans in all patients. Patients with an increased CBF showed
a better outcome than stable or decreased perfusion following
cediranib administration.52
To the best of our knowledge, no clinical ASL studies
are currently available on differentiating responders of antian-
giogenic treatment from pseudoresponders. However, in a
preclinical study ASL-derived rCBF values decreased corre-
sponding to a histological response after bevacizumab admin-
istration in a glioma rat model.53
CURRENT CLINICAL PRACTICE
Perfusion MRI has proven to be useful in treatment evalua-
tion in neuro-oncology. However, not all techniques are
widely available. Two recent large international surveys were
conducted among members of the American Society of Neu-
roradiology (ASNR) and European Society of Neuroradiol-
ogy (ESNR).8,9 Out of 195 institutions included in the
ASNR survey, 151 offered perfusion MRI and 87% thereof
included perfusion MRI in their standard neuro-oncology
imaging protocol. Speciﬁcally for evaluating the presence of
pseudoprogression and pseudoresponse, these percentages
were 96% and 66%, respectively.8 Results from the ESNR
survey on glioma imaging practices in 220 institutions
among 31 European countries showed that perfusion MRI
is commonly utilized among European centers; perfusion
MRI was implemented in the standard imaging protocol in
48% of the centers.9 In both surveys, DSC was shown to be
the most employed perfusion method (87% and 82% for
the ASNR and ESNR, respectively) followed by DCE (41%
and 29%) and ASL (35% and 12%).8,9 However, only half
of the centers that performed perfusion imaging performed
quantitative analysis. In addition, the lack of postprocessing
software was an important reason for not acquiring perfu-
sion imaging.
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NEW DEVELOPMENTS AND PERSPECTIVES
Other Imaging Techniques
According to the consensus recommendations for a standard-
ized brain tumor imaging protocol in clinical trials, the mini-
mum required protocol includes conventional pre- and
postcontrast 3D T1-weighted, axial 2D T2-weighted, and
axial 2D T2-weighted FLAIR sequences as well as axial 2D
diffusion-weighted imaging.54 Despite the higher diagnostic
accuracy of diffusion-weighted imaging compared with con-
ventional MRI for differentiating pseudoprogression from
tumor progression, it is still inferior to perfusion MRI.30
Considering the limitations of the standardized brain tumor
imaging protocol the Response Assessment in Neuro-
Oncology (RANO) working group recently recommended
the use of amino positron emission tomography (PET) imag-
ing in addition to MRI.55 Amino PET is able to differentiate
pseudoprogression from tumor progression with high sensitiv-
ity and speciﬁcity, but it is not known which amino tracer
has the best diagnostic accuracy and a meta-analysis is there-
fore wanted.55 Furthermore, it has not been investigated if
amino PET can outperform perfusion MRI in GBM treat-
ment evaluation. However, hybrid PET/MR systems allow
simultaneous assessment with amino PET and perfusion MRI
and are therefore promising. Finally, perfusion computer
tomography (CT) is capable of measuring rCBV and perme-
ability surface-area product, comparable to Ktrans.56,57 CT
could thus be used for glioblastoma treatment evaluation in
case of MRI contraindications, despite its limited soft-tissue
contrast and limited spatial resolution.
New MRI Perfusion Techniques
Vessel architectural imaging (VAI) is a new perfusion tech-
nique based on the simultaneous acquisition of gradient-echo
and spin-echo DSC images. Differences in susceptibility
effects of the gradient-echo and spin-echo readouts cause a
difference in the relaxation rate curves. Hemodynamic
FIGURE 6: Intravoxel incoherent motion (IVIM) diffusion-weighted imaging in glioblastoma. MRI of a 64-year-old female with a right
frontal glioblastoma as shown on pre- (a) and postcontrast T1-weighted imaging (b). DSC demonstrated elevated perfusion at location
of contrast enhancement (c) and diffusion-weighted imaging showed decreased ADC laterally due to increased cellularity and elevated
ADC in the necrotic core (d). IVIM imaging uses a biexponential model of signal decay (e). The diffusion signal is demonstrated in white
for different b-values. With IVIM this signal decay can be divided into the ﬂow-related pseudodiffusion (red dotted line) and the true
diffusion (blue dotted line). The perfusion fraction (f) results from the signal difference between pseudodiffusion and true diffusion. The
perfusion fraction demonstrated similar results to DSC-rCBV (c). A pseudodiffusion map is also shown (g). IVIM-derived true diffusion
maps (h) are comparable to ADC with elevated values in the necrotic core. ADC = apparent diffusion coefﬁcient, DSC = dynamic
susceptibility contrast, IVIM = intravoxel incoherent motion, rCBV = relative cerebral blood volume.
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properties such as oxygenation, vessel diameter, and ﬂow rate
inﬂuence the relaxation and induce a variability between the
gradient-echo and spin-echo. In a study among 30 patients
with recurrent GBM enrolled in a phase II trial with cedira-
nib, normalization of microcirculation could be detected by
VAI, showing its potential to identify treatment responders.58
Moreover, illustrative case examples of VAI and its measur-
able parameters are included in the aforementioned study.58
Intravoxel incoherent motion (IVIM) is an advanced
diffusion-weighted imaging technique. Many advanced
diffusion-weighted imaging techniques exist,59 but IVIM has
the unique possibility of also allowing perfusion assessment
(Fig. 6). It uses a biexponential model for diffusion calcula-
tion (Fig. 6d). Diffusion is inﬂuenced by microcirculatory
perfusion, mainly affecting results among lower b values.
Using a number of low b values the ﬂow-related pseudodiffu-
sion and perfusion fraction can be derived, which correspond
well to DSC-derived CBV and CBF values.60 So far, only
one study has investigated the ability of IVIM to distinguish
pseudoprogression from tumor progression in GBM patients
using the 90th percentile values of IVIM-derived perfusion
fraction.61 The perfusion fraction was signiﬁcantly higher in
tumor progression compared with pseudoprogression. Cur-
rently, a study is under investigation to compare IVIM and
ASL for the differentiation of tumor and
pseudoprogression.62
Analyses
Analysis of perfusion MRI can be done using many different
methods, of which most are semiquantitative or are deter-
mined by arterial input function. A new postprocessing tech-
nique using wavelet-based reconstruction might further
improve visual assessment, as background structures and ves-
sels are better suppressed.63 Furthermore, radiomics has the
potential to improve complex analysis. Radiomics involves
the mining of quantitative radiological features.64,65 Radio-
mics has already demonstrated its prognostic value in differ-
entiating pseudoprogression from tumor progression based on
textural features of conventional MRI.66–68 Studies including
perfusion parameters in radiomics analyses for treatment eval-
uation in GBM are currently scarce, but preliminary data are
promising.69 Radiomic-derived features can also be combined
with molecular and genetic data (radiogenomics).70 Poten-
tially, radiogenomics can be employed for the differentiation
of pseudoprogression from tumor progression by differences
in molecular signature.71 A relationship between perfusion
imaging-derived parameters and molecular tumor characteris-
tics has been described earlier, with shown correlations
between rCBV and epidermal growth factor receptor variant
III (EGFRvIII) ampliﬁcation.72 However, more research is
needed to establish clear genetic differences between pseudo-
progression and tumor progression and their possible associa-
tion with perfusion parameters. In addition, machine learning
allows automatic decision-making based on supervised or
unsupervised computational learning in a training set. A
study has shown that pseudoprogression can reliably be dis-
tinguished from tumor progression using a support vector
machine learning method, with perfusion MRI parameters
showing the highest sensitivity and speciﬁcity.73
REMAINING QUESTIONS
Standardization of Parameters
The generalizability and quantiﬁcation of the different tech-
niques are large hurdles to overcome for the incorporation of
perfusion MRI in daily clinical care. Cutoff values for differ-
ent perfusion parameters are not standardized and calculation
thereof often requires manual input. Unfortunately, it is not
possible to provide recommendations on optimal cutoff values
considering the widespread thereof used throughout earlier
studies (0.71–3.7) (see also our recent meta-analysis).30
Future work should be aimed at validating cutoff values and
standardized quantiﬁcation of perfusion images allowing iden-
tiﬁcation of the best cutoff for clinical implementation. More-
over, decisions about incorporating perfusion MRI in every
follow-up protocol are to be made.4,54 Currently, the imaging
follow-up interval of treated GBM patients remains debatable
and it is not known if adding perfusion MRI to every follow-
up scan improves clinical decision-making. Finally, compar-
ing perfusion parameters longitudinally in a patient is not
straightforward, as the coregistration of subsequent follow-up
scans remains challenging.74
Role in New Treatments
In recent years, more and more interest has evolved toward
the ﬁeld of immunotherapy. Novel immune checkpoint
blockers are currently under investigation in several phase III
clinical trials. Promising agents include ipilimumab, a cyto-
toxic T lymphocyte-associated antigene 4 (CTLA-4) blocker,
programmed cell death 1-receptor (PD1) blockers such as
pembrolizumab or nivolumab, and genetically modiﬁed T-
cells expressing chimeric antigen receptors (CAR-T
therapy).75–77 Although the long-term effects are not yet fully
understood, treatment-induced inﬂammation and associated
pseudoprogression have also been reported after immunother-
apy. On conventional imaging both increases and decreases in
contrast enhancement and edema have been observed among
responders.47 To aid in treatment evaluation for patients
enrolled in clinical trials studying immunotherapeutic agents,
the immunotherapy response assessment in neuro-oncology
(iRANO) criteria have been established.47 The iRANO thus
far recommends the use of conventional MRI scans along
with clinical criteria for evaluation of immunotherapy.47
According to the iRANO criteria, the occurrence of a new
lesion is not automatically classiﬁed as progressive disease.
Clinically stable patients treated less than 6 months with the
immunotherapeutic agent with the occurrence of a new lesion
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require a second scan after 3 months.47 It is unknown if per-
fusion imaging could overcome this potential delay, hence
perfusion imaging is not yet incorporated in the iRANO rec-
ommendations. The added value of perfusion imaging GBM
patients treated with immunotherapy should be further
studied.
To reduce adverse events associated with conventional
irradiation, proton beam therapy is becoming more available.
Proton beam therapy allows more precise targeting of the
tumor with maximum dose delivery to tumor and minimal
damage to surrounding tissues compared with conventional
photon therapy. Pseudoprogression can also be caused by pro-
ton therapy. A recent study among high-grade gliomas
showed similar incidences of pseudoprogression between con-
ventionally irradiated patients and patients receiving proton
therapy.78 However, little is known about pseudoprogression
and the role of perfusion MRI for treatment follow-up in
GBM patients treated with proton beam therapy.
CONCLUSION
This review contributes to the growing body of evidence for
the added value of perfusion MRI in the treatment evaluation
of GBM. Perfusion MRI has the potential to overcome the
shortcomings of conventional MRI and better distinguish
tumor from treatment-induced processes such as pseudopro-
gression and pseudoresponse. DSC remains the best estab-
lished perfusion method followed by DCE, both of which
show comparable high diagnostic accuracy for differentiating
tumor progression from pseudoprogression. The contrast-
independent method ASL is promising, but studies on its role
in GBM treatment evaluation are thus far limited. Quantiﬁ-
cation of perfusion images remains the largest hurdle to over-
come for standardization of perfusion MRI in imaging
protocols and future work should be aimed thereat.
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